ライム病検査の市場規模、シェア、動向分析レポート：技術別、検査別、サンプル別、最終用途別、地域別、セグメント予測、2024年～2030年

ライム病検査市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のライム病検査の市場規模は2030年までに185億7,000万米ドルに達すると予測され、2024年から2030年までのCAGRは8.2%で成長すると予測されています。

この市場を牽引する主な要因は、有病率の増加、ヘルスケア施設に関する政府の支援政策、ライム病の新しい診断テストの導入です。加えて、ダニ媒介性疾患の罹患率の増加が世界市場をさらに拡大させています。例えば、2022年8月、米国公正保健機構は、ライム病は過去15年間で有病率が大幅に増加し、国家的な懸念となっていると報告しました。

政府のイニシアチブの高まりと予防対策は、市場の成長を著しく促進します。例えば、2022年7月、"New laws seek to boost funding of Lyme disease research "と題された記事は、ニューヨーク州当局が、キャシー・ホーチュル知事の署名した新法により、ライム病とダニ媒介性疾患に対する資金を増加させたことを強調しました。この超党派の措置は、ライム病に関する教育、調査、予防の取り組みを支援するための任意の税額チェックオフボックスを地域に設置するものです。ライム病やマダニが媒介する病気の発生率は高いが、診断検査が不正確なため、実際の患者数はもっと多いと考えられています。

意識の高まりと教育が市場の成長をさらに後押ししています。予防戦略や症状について地域社会を啓蒙する公衆衛生キャンペーンがますます広まっています。このような意識の高まりにより、この病気に一致する症状が現れたときに医療機関を受診する人が増え、信頼性の高い検査オプションに対する需要が高まっています。さらに、ヘルスケア専門家をターゲットとした教育イニシアティブにより、診断と治療のベストプラクティスに関する情報が医療従事者に提供されています。

ライム病検査市場レポートハイライト

• 技術別では、その他の分野が2023年に88.6%の最大売上シェアで市場を牽引しました。高い特異性と感度により検査のゴールドスタンダードとされるこれらの検査が広く採用されたことが、このセグメントの成長に大きく寄与しました。
• 検査に基づくと、血清学的検査分野が2023年に53.1%の最大収益シェアで市場をリードしました。これらの検査は、ボレリア・ブルグドルフェリに対する抗体を検出する上で、広く入手可能で、手頃な価格で、確立され、信頼性が高いため、市場を独占しました。そのため、ヘルスケアプロバイダーや患者にとって、信頼できる利用しやすい選択肢となっています。
• サンプル別では、血液セグメントが2023年に62.4％の最大売上シェアで市場をリードしました。これは、ライム病の原因菌であるボレリア・ブルグドルフェリに対する抗体を効果的に検出できるELISAやウェスタンブロットなどの血液検査によるものです。血液サンプルは入手や取り扱いも容易であるため、広く診断に使用するための実用的な選択肢となっています。
• 最終用途別では、病院セグメントが2023年に58.4%の最大売上シェアで市場をリードしました。第一に、病院は高度な技術と診断ツールを利用できるため、正確でタイムリーな検査が可能です。複雑で重篤な症状を持つ患者を含む病院患者の数が多いため、信頼性の高い診断サービスが必要となり、市場の優位性をさらに高めています。
• 2024年1月、DiaSorin社は2023年12月にLIAISON LymeDetect検査を米国FDAに申請したと発表しました。QIAGEN社との提携により開発されたこの検査は、QIAGEN社独自のQuantiFERON技術、インターフェロン-ガンマ放出アッセイ（IGRA）を用いて、IgG、IgM、T細胞を介した反応を検出します。この新しいソリューションは、米国市場におけるダイヤソリンのリアゾン免疫診断サービスを強化するものであり、QIAGEN社との提携における重要なマイルストーンとなります。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ライム病検査市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• ライム病検査市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
  • パイプライン分析

第4章 ライム病検査市場：技術別推定・動向分析

• 世界のライム病検査市場：技術別ダッシュボード
• 世界のライム病検査市場：技術別変動分析
• 世界のライム病検査市場：技術別収益
• IGRA検査
• その他

第5章 ライム病検査市場：検査別推定・動向分析

• 世界のライム病検査市場：検査別ダッシュボード
• 世界のライム病検査市場：検査別変動分析
• 検査別収益
• 血清学的検査
• リンパ球形質転換試験
• 尿抗原検査
• 免疫蛍光染色
• 核酸検査

第6章 ライム病検査市場： サンプル別推定・動向分析

• 世界のライム病検査市場：サンプル別ダッシュボード
• 世界のライム病検査市場：サンプル別変動分析
• サンプル別収益
• 血
• 尿
• 脳脊髄液
• その他

第7章 ライム病検査市場：最終用途別推定・動向分析

• 世界のライム病検査市場：最終用途別ダッシュボード
• 世界のライム病検査市場：最終用途別変動分析
• 最終用途別収益
• 病院
• 診断検査室
• その他

第8章 ライム病検査市場：技術、サンプル、検査、最終用途別の地域別推定・動向分析

• 地域別ダッシュボード
• 市場規模と予測動向分析、2018年から2030年
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

第9章 競合情勢

• 企業/競合の分類
• ベンダー情勢
  • 主要販売代理店およびチャネルパートナーのリスト
  • 主要顧客
  • 主要企業の市場シェア分析、2023年
  • DiaSorin SpA
  • BIOMERIEUX
  • Oxford Immunotec
  • Bio-Rad Laboratories, Inc.
  • Thermo Fisher Scientific, Inc.
  • T2 Biosystems
  • IGeneX
  • Gold Standard Diagnostics
  • ZEUS Scientific
  • Trinity Biotech

List of Tables

• Table 1 List of abbreviation
• Table 2 North America Lyme disease testing market, by region, 2018 - 2030 (USD Million)
• Table 3 North America Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
• Table 4 North America Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
• Table 5 North America Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
• Table 6 North America Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
• Table 7 U.S Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
• Table 8 U.S Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
• Table 9 U.S Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
• Table 10 U.S Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
• Table 11 Canada Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
• Table 12 Canada Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
• Table 13 Canada Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
• Table 14 Canada Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
• Table 15 Mexico Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
• Table 16 Mexico Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
• Table 17 Mexico Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
• Table 18 Mexico Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
• Table 19 Europe Lyme disease testing market, by region, 2018 - 2030 (USD Million)
• Table 20 Europe Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
• Table 21 Europe Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
• Table 22 Europe Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
• Table 23 Europe Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
• Table 24 Germany Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
• Table 25 Germany Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
• Table 26 Germany Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
• Table 27 Germany Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
• Table 28 UK Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
• Table 29 UK Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
• Table 30 UK Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
• Table 31 UK Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
• Table 32 France Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
• Table 33 France Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
• Table 34 France Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
• Table 35 France Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
• Table 36 Italy Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
• Table 37 Italy Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
• Table 38 Italy Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
• Table 39 Italy Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
• Table 40 Spain Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
• Table 41 Spain Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
• Table 42 Spain Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
• Table 43 Spain Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
• Table 44 Denmark Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
• Table 45 Denmark Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
• Table 46 Denmark Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
• Table 47 Denmark Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
• Table 48 Sweden Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
• Table 49 Sweden Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
• Table 50 Sweden Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
• Table 51 Sweden Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
• Table 52 Norway Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
• Table 53 Norway Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
• Table 54 Norway Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
• Table 55 Norway Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
• Table 56 Asia Pacific Lyme disease testing market, by region, 2018 - 2030 (USD Million)
• Table 57 Asia Pacific Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
• Table 58 Asia Pacific Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
• Table 59 Asia Pacific Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
• Table 60 Asia Pacific Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
• Table 61 China Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
• Table 62 China Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
• Table 63 China Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
• Table 64 China Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
• Table 65 Japan Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
• Table 66 Japan Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
• Table 67 Japan Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
• Table 68 Japan Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
• Table 69 India Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
• Table 70 India Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
• Table 71 India Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
• Table 72 India Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
• Table 73 South Korea Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
• Table 74 South Korea Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
• Table 75 South Korea Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
• Table 76 South Korea Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
• Table 77 Australia Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
• Table 78 Australia Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
• Table 79 Australia Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
• Table 80 Australia Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
• Table 81 Thailand Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
• Table 82 Thailand Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
• Table 83 Thailand Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
• Table 84 Thailand Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
• Table 85 Latin America Lyme disease testing market, by region, 2018 - 2030 (USD Million)
• Table 86 Latin America Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
• Table 87 Latin America Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
• Table 88 Latin America Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
• Table 89 Latin America Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
• Table 90 Brazil Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
• Table 91 Brazil Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
• Table 92 Brazil Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
• Table 93 Brazil Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
• Table 94 Argentina Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
• Table 95 Argentina Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
• Table 96 Argentina Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
• Table 97 Argentina Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
• Table 98 MEA Lyme disease testing market, by region, 2018 - 2030 (USD Million)
• Table 99 MEA Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
• Table 100 MEA Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
• Table 101 MEA Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
• Table 102 MEA Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
• Table 103 South Africa Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
• Table 104 South Africa Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
• Table 105 South Africa Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
• Table 106 South Africa Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
• Table 107 Saudi Arabia Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
• Table 108 Saudi Arabia Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
• Table 109 Saudi Arabia Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
• Table 110 Saudi Arabia Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
• Table 111 UAE Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
• Table 112 UAE Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
• Table 113 UAE Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
• Table 114 UAE Lyme disease testing market, by end use, 2018 - 2030 (USD Million)
• Table 115 Kuwait Lyme disease testing market, by technology, 2018 - 2030 (USD Million)
• Table 116 Kuwait Lyme disease testing market, by testing, 2018 - 2030 (USD Million)
• Table 117 Kuwait Lyme disease testing market, by sample, 2018 - 2030 (USD Million)
• Table 118 Kuwait Lyme disease testing market, by end use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in North America
• Fig. 5 Primary interviews in Europe
• Fig. 6 Primary interviews in APAC
• Fig. 7 Primary interviews in Latin America
• Fig. 8 Primary interviews in MEA
• Fig. 9 Market research approaches
• Fig. 10 Value-chain-based sizing & forecasting
• Fig. 11 QFD modeling for market share assessment
• Fig. 12 Market formulation & validation
• Fig. 13 Lyme Disease Testing market: market outlook
• Fig. 14 Lyme Disease Testing competitive insights
• Fig. 15 Parent market outlook
• Fig. 16 Related/ancillary market outlook
• Fig. 17 Lyme Disease Testing market driver impact
• Fig. 18 Lyme Disease Testing market restraint impact
• Fig. 19 Lyme Disease Testing market: Technology movement analysis
• Fig. 20 Lyme Disease Testing market: Technology outlook and key takeaways
• Fig. 21 IGRA Testing market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Lyme Disease Testing market: Testing movement analysis
• Fig. 24 Lyme Disease Testing market: Testing outlook and key takeaways
• Fig. 25 Serological test market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 ELISA market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Western Blot market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 Lymphocytic transformation test market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 29 Urine Antigen Testing market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 30 Immunofluorescent Staining market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Nucleic Acid Test market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 Lyme Disease Testing market: Sample movement analysis
• Fig. 33 Lyme Disease Testing market: Sample outlook and key takeaways
• Fig. 34 Blood market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 35 Urine market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 36 CSF market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 38 Lyme Disease Testing market: End Use movement analysis
• Fig. 39 Lyme Disease Testing market: End Use outlook and key takeaways
• Fig. 40 Hospitals market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 41 Diagnostic Laboratories market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 42 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 43 Global Lyme Disease Testing market: Regional movement analysis
• Fig. 44 Global Lyme Disease Testing market: Regional outlook and key takeaways
• Fig. 45 Global Lyme Disease Testing market share and leading players
• Fig. 46 North America, by country
• Fig. 47 North America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 U.S key country dynamics
• Fig. 49 U.S market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Canada key country dynamics
• Fig. 51 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 Mexico key country dynamics
• Fig. 53 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 UK key country dynamics
• Fig. 56 UK market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 Germany key country dynamics
• Fig. 58 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 France key country dynamics
• Fig. 60 France market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Italy key country dynamics
• Fig. 62 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 63 Spain key country dynamics
• Fig. 64 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 65 Denmark key country dynamics
• Fig. 66 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 67 Sweden key country dynamics
• Fig. 68 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 69 Norway key country dynamics
• Fig. 70 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 71 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 72 China key country dynamics
• Fig. 73 China market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 74 Japan key country dynamics
• Fig. 75 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 76 India key country dynamics
• Fig. 77 India market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 78 Thailand key country dynamics
• Fig. 79 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 80 South Korea key country dynamics
• Fig. 81 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 82 Australia key country dynamics
• Fig. 83 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 84 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 85 Brazil key country dynamics
• Fig. 86 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 87 Argentina key country dynamics
• Fig. 88 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 89 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 90 South Africa key country dynamics
• Fig. 91 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 92 Saudi Arabia key country dynamics
• Fig. 93 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 94 UAE key country dynamics
• Fig. 95 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 96 Kuwait key country dynamics
• Fig. 97 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 98 Market share of key market players- Lyme Disease Testing market

Lyme Disease Testing Market Growth & Trends:

The global lyme disease testing market size is anticipated to reach USD 18.57 billion by 2030 and is projected to grow at a CAGR of 8.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The primary factors driving this market are the increasing prevalence, supportive government policies regarding healthcare facilities, and the introduction of new diagnostic tests for Lyme disease. In addition, the growing incidence of tick-borne diseases further expands the global market. For instance, in August 2022, the U.S. Fair Health Organization reported that Lyme disease has significantly increased in prevalence over the past 15 years, becoming a growing national concern.

Growing government initiatives and preventive measures significantly drive the market growth. For instance, in July 2022, an article titled "New laws seek to boost funding of Lyme disease research" highlighted that New York officials have increased funding for Lyme disease and tick-borne illnesses through a new law signed by Governor Kathy Hochul. This bipartisan measure will establish a voluntary tax check-off box to support education, research, and prevention efforts related to the disease in the region. Despite the high incidence of Lyme and tick-borne illnesses, it is believed that the actual number of cases is much higher due to inaccurate diagnostic testing.

Heightened awareness and education are further propelling market growth. Public health campaigns to educate communities about prevention strategies and symptoms have become increasingly prevalent. This growing awareness leads to more individuals seeking medical attention when they exhibit symptoms consistent with the disease, thereby driving demand for reliable testing options. Furthermore, educational initiatives targeting healthcare professionals ensure they remain informed about best practices for diagnosis and treatment.

Lyme Disease Testing Market Report Highlights:

• Based on technology, the other segment led the market with the largest revenue share of 88.6% in 2023. The widespread adoption of these tests, considered the gold standard for testing due to their high specificity and sensitivity, significantly contributed to the growth of this segment
• Based on testing, the serological test segment led the market with the largest revenue share of 53.1% in 2023. These tests dominated the market as they are widely available, affordable, established, and reliable in detecting antibodies against Borrelia burgdorferi. This makes them a trusted and accessible option for healthcare providers and patients
• Based on sample, the blood segment led the market with the largest revenue share of 62.4% in 2023. This is due to the blood tests, such as ELISA and Western blot, which can effectively detect antibodies against Borrelia burgdorferi, the bacteria causing Lyme disease. Blood samples are also easy to obtain and handle, making them a practical choice for widespread diagnostic use
• Based on end use, the hospital segment led the market with the largest revenue share of 58.4% in 2023. Firstly, hospitals can access advanced technology and diagnostic tools, enabling accurate & timely testing. The high hospital patient volume, including those with complex and severe symptoms, necessitates reliable diagnostic services, further driving their market dominance
• In January 2024, DiaSorin announced that it submitted the LIAISON LymeDetect test to the U.S. FDA in December 2023. Developed in partnership with QIAGEN, this test detects IgG, IgM, and T-cell mediated responses using QIAGEN's proprietary QuantiFERON technology, an Interferon-Gamma Release Assay (IGRA). This novel solution will enhance DiaSorin's LIAISON immunodiagnostic offerings in the U.S. market, representing a significant milestone in its collaboration with QIAGEN

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Technology
  • 1.2.2. Testing
  • 1.2.3. Sample
  • 1.2.4. End Use
  • 1.2.5. Regional scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Technology outlook
  • 2.2.2. Testing outlook
  • 2.2.3. Sample outlook
  • 2.2.4. End Use outlook
  • 2.2.5. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Lyme Disease Testing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rise in prevalence of lyme disease
    • 3.2.1.2. Rising number of research programs for Lyme disease diagnosis
    • 3.2.1.3. Launch of new lyme diagnostic tests
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Lack of awareness regarding testing
• 3.3. Lyme Disease Testing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pipeline Analysis

Chapter 4. Lyme Disease Testing Market: Technology Estimates & Trend Analysis

• 4.1. Global Lyme Disease Testing Market: Technology Dashboard
• 4.2. Global Lyme Disease Testing Market: Technology Movement Analysis
• 4.3. Global Lyme Disease Testing Market by Technology, Revenue
• 4.4. IGRA Testing
  • 4.4.1. IGRA Testing market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Others
  • 4.5.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Lyme Disease Testing Market: Testing Estimates & Trend Analysis

• 5.1. Global Lyme Disease Testing Market: Testing Dashboard
• 5.2. Global Lyme Disease Testing Market: Testing Movement Analysis
• 5.3. Global Lyme Disease Testing Market Estimates and Forecasts, by Testing, Revenue (USD Million)
• 5.4. Serological Test
  • 5.4.1. Serological Test market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. ELISA
    • 5.4.2.1. ELISA market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Western Blot
    • 5.4.3.1. Western blot market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Lymphocytic Transformation Test
  • 5.5.1. Lymphocytic transformation test market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Urine Antigen Testing
  • 5.6.1. Urine Antigen Testing market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Immunofluorescent Staining
  • 5.7.1. Immunofluorescent Staining market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Nucleic Acid Test
  • 5.8.1. Nucleic Acid Test market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Lyme Disease Testing Market: Sample Estimates & Trend Analysis

• 6.1. Global Lyme Disease Testing Market: Sample Dashboard
• 6.2. Global Lyme Disease Testing Market: Sample Movement Analysis
• 6.3. Global Lyme Disease Testing Market Estimates and Forecasts, By Sample, Revenue (USD Million)
• 6.4. Blood
  • 6.4.1. Blood market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Urine
  • 6.5.1. Urine market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. CSF
  • 6.6.1. CSF market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Lyme Disease Testing Market: End Use Estimates & Trend Analysis

• 7.1. Global Lyme Disease Testing Market: End Use Dashboard
• 7.2. Global Lyme Disease Testing Market: End Use Movement Analysis
• 7.3. Global Lyme Disease Testing Market Estimates and Forecasts, By End Use, Revenue (USD Million)
• 7.4. Hospitals
  • 7.4.1. Hospitals market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Diagnostic Laboratories
  • 7.5.1. Diagnostic Laboratories market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Others
  • 7.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Lyme Disease Testing Market: Regional Estimates & Trend Analysis by Technology, Sample, Testing, and End Use

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company/Competition Categorization
• 9.2. Vendor Landscape
  • 9.2.1. List of key distributors and channel partners
  • 9.2.2. Key customers
  • 9.2.3. Key company market share analysis, 2023
  • 9.2.4. DiaSorin S.p.A
    • 9.2.4.1. Company overview
    • 9.2.4.2. Financial performance
    • 9.2.4.3. Product benchmarking
    • 9.2.4.4. Strategic initiatives
  • 9.2.5. BIOMERIEUX
    • 9.2.5.1. Company overview
    • 9.2.5.2. Financial performance
    • 9.2.5.3. Product benchmarking
    • 9.2.5.4. Strategic initiatives
  • 9.2.6. Oxford Immunotec
    • 9.2.6.1. Company overview
    • 9.2.6.2. Financial performance
    • 9.2.6.3. Product benchmarking
    • 9.2.6.4. Strategic initiatives
  • 9.2.7. Bio-Rad Laboratories, Inc.
    • 9.2.7.1. Company overview
    • 9.2.7.2. Financial performance
    • 9.2.7.3. Product benchmarking
    • 9.2.7.4. Strategic initiatives
  • 9.2.8. Thermo Fisher Scientific, Inc.
    • 9.2.8.1. Company overview
    • 9.2.8.2. Financial performance
    • 9.2.8.3. Product benchmarking
    • 9.2.8.4. Strategic initiatives
  • 9.2.9. T2 Biosystems
    • 9.2.9.1. Company overview
    • 9.2.9.2. Financial performance
    • 9.2.9.3. Product benchmarking
    • 9.2.9.4. Strategic initiatives
  • 9.2.10. IGeneX
    • 9.2.10.1. Company overview
    • 9.2.10.2. Financial performance
    • 9.2.10.3. Product benchmarking
    • 9.2.10.4. Strategic initiatives
  • 9.2.11. Gold Standard Diagnostics
    • 9.2.11.1. Company overview
    • 9.2.11.2. Financial performance
    • 9.2.11.3. Product benchmarking
    • 9.2.11.4. Strategic initiatives
  • 9.2.12. ZEUS Scientific
    • 9.2.12.1. Company overview
    • 9.2.12.2. Financial performance
    • 9.2.12.3. Product benchmarking
    • 9.2.12.4. Strategic initiatives
  • 9.2.13. Trinity Biotech
    • 9.2.13.1. Company overview
    • 9.2.13.2. Financial performance
    • 9.2.13.3. Product benchmarking
    • 9.2.13.4. Strategic initiatives